Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
RESEARCH TOOLSreports
MLTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$31.42 - $58.26
Previous CloseN/A
Volume45.38K
Average Volume (3M)481.74K
Market Cap
$2.45B
Enterprise Value$2.98B
Total Cash (Recent Filing)$39.51M
Total Debt (Recent Filing)$282.58K
Price to Earnings (P/E)―
Beta1.30
Next Earnings
May 08, 2025EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.89
Shares Outstanding63,282,726
10 Day Avg. Volume433,055
30 Day Avg. Volume481,741
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-21.01
Forecast
1Y Price Target
$77.44Price Target Upside93.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
---
MoonLake Immunotherapeutics News
PremiumCompany Announcements
MoonLake Immunotherapeutics Secures $500M Financing for Growth
PremiumCompany Announcements
MoonLake Immunotherapeutics Advances Clinical Trials in 2024
---
Bulls Say, Bears Say
Bulls Say
Capital AccessMLTX announced access to non-dilutive capital of up to $500mn via a newly secured credit facility.
Clinical Trial ProgressMLTX announced the initiation of three studies of IL-17A/F nanobody sonelokimab (SLK) in adolescent patients with hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP), and axial spondyloarthritis (axSpA), which is seen as positive progress in expanding the market opportunity for SLK.
Financial PositionMLTX's strong balance sheet, with end of 3Q24 cash of $493.9M and a guided runway to YE26, should provide solid support for continued clinical development activities.
Bears Say
Clinical Trial RisksThe biggest hurdle in adolescent patients is safety, and optimism in SLK is based on a strong safety profile shown in clinical studies.
---
Ownership Overview
27.07% Insiders
17.95% Mutual Funds
0.28% Other Institutional Investors
54.01% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MLTX FAQ
What was MoonLake Immunotherapeutics’s price range in the past 12 months?
MoonLake Immunotherapeutics lowest stock price was $31.42 and its highest was $58.26 in the past 12 months.
What is MoonLake Immunotherapeutics’s market cap?
MoonLake Immunotherapeutics’s market cap is $2.45B.
When is MoonLake Immunotherapeutics’s upcoming earnings report date?
MoonLake Immunotherapeutics’s upcoming earnings report date is May 08, 2025 which is in 15 days.
How were MoonLake Immunotherapeutics’s earnings last quarter?
MoonLake Immunotherapeutics released its earnings results on Feb 26, 2025. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.62 by -$0.1.
Is MoonLake Immunotherapeutics overvalued?
According to Wall Street analysts MoonLake Immunotherapeutics’s price is currently Undervalued.
Does MoonLake Immunotherapeutics pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
What is MoonLake Immunotherapeutics’s EPS estimate?
MoonLake Immunotherapeutics’s EPS estimate is -0.75.
How many shares outstanding does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics has 63,282,726 shares outstanding.
What happened to MoonLake Immunotherapeutics’s price movement after its last earnings report?
MoonLake Immunotherapeutics reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.62. Following the earnings report the stock price went up 4.027%.
Which hedge fund is a major shareholder of MoonLake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
---
MoonLake Immunotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$77.44 (93.60% Upside)
$77.44 (93.60% Upside)
Blogger Sentiment
Bullish
MLTX Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 71.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.19%
12-Months-Change
Fundamentals
Return on Equity
-25.24%
Trailing 12-Months
Asset Growth
-9.23%
Trailing 12-Months
Company Description
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
---
MLTX Stock 12 Month Forecast
Average Price Target
$77.44
▲(93.60% Upside)
Technical Analysis
Amicus
―
ImmunityBio
―
Apellis Pharmaceuticals
―
Crinetics Pharmaceuticals
―
Immunovant
―
Best Analysts Covering MLTX
1 Year
1 Year Success Rate
10/21 ratings generated profit
1 Year Average Return
+89.60%
reiterated a buy rating 21 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +89.60% per trade.
---